Bitcoin halving
What does that mean?
$2.8T
Total marketcap
$128.41B
Total volume
BTC 50.01%     ETH 15.37%
Dominance

OPKO Health, Inc. OPK.TA Stock

439.4 ILA {{ price }} 10.596528% {{change_pct}}%
COUNTRY
Israel
Exchange
Tel Aviv
Market Cap
3.06B ILA
LOW - HIGH [24H]
389.3 - 460 ILA
VOLUME [24H]
2.15M ILA
{{ volume }}
P/E Ratio
0
Earnings per share
-0.91 ILA

OPKO Health, Inc. Price Chart

OPKO Health, Inc. OPK.TA Financial and Trading Overview

OPKO Health, Inc. stock price 439.4 ILA
Previous Close 559.4 ILA
Open 545 ILA
Bid 560.6 ILA x N/A
Ask 562 ILA x N/A
Day's Range 532.6 - 555.9 ILA
52 Week Range 369.9 - 986.5 ILA
Volume 663.98K ILA
Avg. Volume 511.49K ILA
Market Cap 4.15B ILA
Beta (5Y Monthly) 1.660563
PE Ratio (TTM) N/A
EPS (TTM) -0.91 ILA
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A

OPK.TA Valuation Measures

Enterprise Value 4.5B ILA
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 4.545036
Price/Book (mrq) 267.3307
Enterprise Value/Revenue 4.936
Enterprise Value/EBITDA -46.553

Trading Information

OPKO Health, Inc. Stock Price History

Beta (5Y Monthly) 1.660563
52-Week Change -36.33%
S&P500 52-Week Change 20.43%
52 Week High 986.5 ILA
52 Week Low 369.9 ILA
50-Day Moving Average 563.13 ILA
200-Day Moving Average 547.17 ILA

OPK.TA Share Statistics

Avg. Volume (3 month) 511.49K ILA
Avg. Daily Volume (10-Days) 411.19K ILA
Shares Outstanding 772.65M
Float 418.94M
Short Ratio N/A
% Held by Insiders 46.07%
% Held by Institutions 24.25%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -31.91%
Operating Margin (ttm) -22.36%
Gross Margin 25.01%
EBITDA Margin -10.60%

Management Effectiveness

Return on Assets (ttm) -5.69%
Return on Equity (ttm) -18.39%

Income Statement

Revenue (ttm) 912.55M ILA
Revenue Per Share (ttm) 1.23 ILA
Quarterly Revenue Growth (yoy) -27.80%
Gross Profit (ttm) 214.3M ILA
EBITDA -96765000 ILA
Net Income Avi to Common (ttm) -291239008 ILA
Diluted EPS (ttm) -1.43
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 110.83M ILA
Total Cash Per Share (mrq) 0.14 ILA
Total Debt (mrq) 293.31M ILA
Total Debt/Equity (mrq) 18.9 ILA
Current Ratio (mrq) 1.827
Book Value Per Share (mrq) 2.008

Cash Flow Statement

Operating Cash Flow (ttm) -97980000 ILA
Levered Free Cash Flow (ttm) 226.36M ILA

Profile of OPKO Health, Inc.

Country Israel
State FL
City Miami
Address 4400 Biscayne Boulevard
ZIP 33137
Phone 305-575-4100
Website https://www.opko.com
Industry Diagnostics & Research
Sector(s) Healthcare
Full Time Employees 4196

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Q&A For OPKO Health, Inc. Stock

What is a current OPK.TA stock price?

OPKO Health, Inc. OPK.TA stock price today per share is 439.4 ILA.

How to purchase OPKO Health, Inc. stock?

You can buy OPK.TA shares on the Tel Aviv exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for OPKO Health, Inc.?

The stock symbol or ticker of OPKO Health, Inc. is OPK.TA.

Which industry does the OPKO Health, Inc. company belong to?

The OPKO Health, Inc. industry is Diagnostics & Research.

How many shares does OPKO Health, Inc. have in circulation?

The max supply of OPKO Health, Inc. shares is 6.97M.

What is OPKO Health, Inc. Price to Earnings Ratio (PE Ratio)?

OPKO Health, Inc. PE Ratio is now.

What was OPKO Health, Inc. earnings per share over the trailing 12 months (TTM)?

OPKO Health, Inc. EPS is -0.91 ILA over the trailing 12 months.

Which sector does the OPKO Health, Inc. company belong to?

The OPKO Health, Inc. sector is Healthcare.